Navigation Links
M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting

TSX: CTI OTCBB: CHKT

VANCOUVER, April 02, 2007 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the "Company") , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that the University of Texas M. D. Anderson Cancer Center's abstract, "Inhibition of primary growth and distant metastasis with a CXCR4 antagonist in a mouse model of breast cancer" authored by Eugene H. Huang, Balraj Singh, Laura Vincent, Massimo Cristofanilli, Kailash Mosalpuria, Caimiao Wei, and Anthony Lucci, has been accepted by the American Association for Cancer Research ("AACR") for oral presentation at its 2007 Annual Meeting being held in Los Angeles, California. The presentation will be given by Dr. Eugene Huang on Wednesday, April 18, 2007, as part of the Experimental Therapeutics Mini-symposium.

The Meeting is expected to attract more than 15,000 participants from 60 countries to discuss and hear presentations on new and significant discoveries in basic, clinical, and translational cancer research. The AACR hopes to identify the most compelling science and ensure that the latest advances in all areas of cancer research and specifically the most important emerging research fields are fully covered.

Researchers at the M. D. Anderson Cancer Center have been studying the ability of CTCE-9908 to inhibit the metastasis of a human breast cancer in preclinical models as part of a collaborative research effort with the Company.

About CTCE-9908

CTCE-9908 is a peptide analog of the Chemokine SDF-1, and an antagonist of its receptor, CXCR4. SDF-1 is the only known naturally occurring chemokine that binds to CXCR4, which is present on cancer cells of over 30 different tumor types. Activation by SDF-1 is believed to be critical in angiogenesis and in the metastasis (or spread) of cancer cells to distant locations in the body, where they
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Protox Announces Positive Clinical Data from Prostate Cancer Study
7. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
8. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
9. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
10. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:1/23/2015)... ANGELES , Jan. 23, 2015 A lot of ... best methods for treating  certain illnesses, injuries, or conditions. As ... replace previous treatment methods with ones that they consider to ... hernias, there is not one textbook method of treatment that ...
(Date:1/23/2015)... WYNNEWOOD, Pa. , Jan. 23, 2015  MedScope ( ... has been nominated for a 2015 Connected World ... Personal Emergency Response System (mPERS), that can be used ... M2M technology partner.  In nominating MedScope, ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... Kurtz Resigns as President and Chief Executive Officer; Evelyn ... Appointed Acting Chief Executive Officer -, LA JOLLA, Calif., ... announced that Neil Kurtz, M.D., is,resigning as President, Chief Executive ... 31, 2008. Dr. Kurtz is leaving TorreyPines,to assume the role ...
... a San Diego biotech company, developed the first method to ... iron and its distribution in the body. This ... millions of people worldwide such as anemias and iron overload ... the amount of hepcidin in the blood. When levels ...
... Patients and Helps ... Money for Make-A-Wish Foundation, PITTSBURGH, Aug. 8 Aethon ... robot to children,s,hospitals across the country. Also, Aethon will make ... that is deployed. The JR,TUG was initially introduced at the ...
... surgery, pair of studies finds , , FRIDAY, Aug. 8 (HealthDay ... not be accurate for obese men, leaving them more vulnerable ... effective for them, a new pair of studies found. , ... aggressive form of the disease," said Dr. Stephen Freedland, an ...
... Cervical Cancer Screening Participants Receive $15 ... ... Aug. 8 Keystone Mercy Health Plan, the,largest medical assistance ... Inc. (DVCH), a,non-profit organization that provides community-based, primary medical,dental and ...
... the Harvard School of Public Health, today expressed "deep ... Kamiar Alaei, a 2007 Masters of Science graduate of ... The brothers are Iranian physicians working on the prevention ... in their country." , , "There is concern for their ...
Cached Medicine News:Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 2Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 3Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 4Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 5Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 6Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 7Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 3Health News:Obese Men Face Twin Threat From Prostate Cancer 2Health News:Keystone Mercy and DVCH to Offer Screenings for National Health Center Week 2
... The RSV ASR contains primers and a ... Respiratory Syncytial Virus (RSV). In addition, this ... probe for a,separate sample processing control. This ... FAM and Texas Red reporter dyes such ...
Digital Ultrasonic Diagnostic Imaging System...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Pefakit PiCT LMWH Controls...
Medicine Products: